Cancer screening startup Ezra has raised $18 million in investment funds in a round led by FirstMark Capital in New York City.
It plans to use the funds to expand its medical imaging artificial intelligence offerings for MRI-based cancer screening. It also plans to launch Ezra COVID 360, a low-dose CT scan of the lungs combined with an antibody blood test, which it will offer individuals for $390 in New York City starting June 1.
Ezra will offer 50 free exams to medical providers and first responders who have been providing care during the COVID-19 pandemic, the company said.
